Joseph M Chan
Overview
Explore the profile of Joseph M Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Quintanal-Villalonga A, Chan J, Masilionis I, Gao V, Xie Y, Allaj V, et al.
STAR Protoc
. 2022 Oct;
3(4):101776.
PMID: 36313536
We report a protocol for obtaining high-quality single-cell transcriptomics data from human lung biospecimens acquired from core needle biopsies, fine-needle aspirates, surgical resection, and pleural effusions. The protocol relies upon...
12.
Chan J, Zaidi S, Love J, Zhao J, Setty M, Wadosky K, et al.
Science
. 2022 Aug;
377(6611):1180-1191.
PMID: 35981096
Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the molecular mechanisms driving this plasticity remain unclear. Using murine organoid and genetically engineered...
13.
Nguyen E, Taniguchi H, Chan J, Zhan Y, Chen X, Qiu J, et al.
J Thorac Oncol
. 2022 Jun;
17(8):1014-1031.
PMID: 35691495
Introduction: SCLC is a highly aggressive neuroendocrine tumor that is characterized by early acquired therapeutic resistance and modest benefit from immune checkpoint blockade (ICB). Repression of the major histocompatibility complex...
14.
Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan Y, Chavan S, et al.
Cancer Res
. 2021 Nov;
82(3):472-483.
PMID: 34815254
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet...
15.
Quintanal-Villalonga A, Taniguchi H, Zhan Y, Hasan M, Chavan S, Meng F, et al.
J Hematol Oncol
. 2021 Oct;
14(1):170.
PMID: 34656143
Background: Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell and squamous cell (LUSC) histologic...
16.
Chan J, Quintanal-Villalonga A, Gao V, Xie Y, Allaj V, Chaudhary O, et al.
Cancer Cell
. 2021 Oct;
39(11):1479-1496.e18.
PMID: 34653364
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity...
17.
Quintanal-Villalonga A, Taniguchi H, Zhan Y, Hasan M, Chavan S, Meng F, et al.
Cancer Discov
. 2021 Jun;
11(12):3028-3047.
PMID: 34155000
Significance: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here,...
18.
Quintanal-Villalonga A, Chan J, Yu H, Peer D, Sawyers C, Sen T, et al.
Nat Rev Clin Oncol
. 2020 Mar;
17(6):382.
PMID: 32203275
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
19.
Quintanal-Villalonga A, Chan J, Yu H, Peer D, Sawyers C, Sen T, et al.
Nat Rev Clin Oncol
. 2020 Mar;
17(6):360-371.
PMID: 32152485
Lineage plasticity, the ability of cells to transition from one committed developmental pathway to another, has been proposed as a source of intratumoural heterogeneity and of tumour adaptation to an...
20.
Schoenfeld A, Chan J, Kubota D, Sato H, Rizvi H, Daneshbod Y, et al.
Clin Cancer Res
. 2020 Jan;
26(11):2654-2663.
PMID: 31911548
Purpose: Patterns of resistance to first-line osimertinib are not well-established and have primarily been evaluated using plasma assays, which cannot detect histologic transformation and have differential sensitivity for copy number...